scholarly journals Clinical practice patterns and cost-effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

Cancer ◽  
2010 ◽  
Vol 116 (16) ◽  
pp. 3980-3981
Author(s):  
Patrick Fitzgibbons ◽  
Mary Kay Washington ◽  
Douglas Murphy
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Practice Patterns ◽  
Breast Cancer Patients ◽  
Clinical Practice Patterns ◽  
Testing Strategies ◽  
Epidermal Growth

scholarly journals Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients

Cancer ◽  
2009 ◽  
Vol 115 (22) ◽  
pp. 5166-5174 ◽  
Author(s):  
Kathryn A. Phillips ◽  
Deborah A. Marshall ◽  
Jennifer S. Haas ◽  
Elena B. Elkin ◽  
Su-Ying Liang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cost Effectiveness ◽  
Cancer Patients ◽  
Practice Patterns ◽  
Breast Cancer Patients ◽  
Clinical Practice Patterns ◽  
Testing Strategies ◽  
Epidermal Growth

scholarly journals Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Qiaoping Xu ◽  
Li Yuanyuan ◽  
Zhu Jiejing ◽  
Liu Jian ◽  
Li Qingyu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Partial Response ◽  
Cancer Patients ◽  
Transition Probabilities ◽  
Complete Response ◽  
Sensitivity Analyses ◽  
Half Cycle ◽  
Breast Cancer Patients ◽  
Grade 3

Abstract Background Breast cancer is the most common cancer among women in China. Amplification of the Human epidermal growth factor receptor type 2 (HER2) gene is present and overexpressed in 18–20% of breast cancers and historically has been associated with inferior disease-related outcomes. There has been increasing interest in de-escalation of therapy for low-risk disease. This study analyzes the cost-effectiveness of Doxorubicin/ Cyclophosphamide/ Paclitaxel/ Trastuzumab (AC-TH) and Docetaxel/Carboplatin/Trastuzumab(TCH) from payer perspective over a 5 year time horizon. Methods A half-cycle corrected Markov model was built to simulate the process of breast cancer events and death occurred in both AC-TH and TCH armed patients. Cost data came from studies based on a Chinese hospital. One-way sensitivity analyses as well as second-order Monte Carlo and probabilistic sensitivity analyses were performed.The transition probabilities and utilities were extracted from published literature, and deterministic sensitivity analyses were conducted. Results We identified 41 breast cancer patients at Hangzhou First People’s Hospital, among whom 15 (60%) had a partial response for AC-TH treatment and 13 (81.25%) had a partial response for TCH treatment.No cardiac toxicity was observed. Hematologic grade 3 or 4 toxicities were observed in 1 of 28 patients.Nonhematologic grade 3 or 4 toxicities with a reverse pattern were observed in 6 of 29 patients. The mean QALY gain per patient compared with TCH was 0.25 with AC-TH, while the incremental costs were $US13,142. The incremental cost-effectiveness ratio (ICER) of AC-TH versus TCH was $US 52,565 per QALY gained. Conclusions This study concluded that TCH neoadjuvant chemotherapy was feasible and active in HER2-overexpressing breast cancer patients in terms of the pathological complete response, complete response, and partial response rates and manageable toxicities.

Elderly breast cancer patients treated with Nab-paclitaxel: Results in real clinical practice

2020 ◽  
Author(s):  
Marta Gascón Ruiz ◽  
Diego Casas Deza ◽  
Miguel Lafuente Blasco ◽  
Andrea Sesma Goñi ◽  
Mara Cruellas Lapeña ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Real Clinical Practice

scholarly journals Medical ovariectomy in menopausal breast cancer patients with high testosterone levels: a further step toward tailored therapy

2017 ◽  
Vol 24 (11) ◽  
pp. C21-C29 ◽  
Author(s):  
Giorgio Secreto ◽  
Paola Muti ◽  
Milena Sant ◽  
Elisabetta Meneghini ◽  
Vittorio Krogh
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Serum Testosterone ◽  
Late Relapse ◽  
Breast Cancer Patients ◽  
Estrogen Receptor Positive ◽  
Epidermal Growth

Five years of adjuvant therapy with anti-estrogens reduce the incidence of disease progression by about 50% in estrogen receptor-positive breast cancer patients, but late relapse can still occur after anti-estrogens have been discontinued. In these patients, excessive androgen production may account for renewed excessive estrogen formation and increased risks of late relapse. In the 50% of patients who do not benefit with anti-estrogens, the effect of therapy is limited by de novo or acquired resistance to treatment. Androgen receptor and epidermal growth factor receptor overexpression are recognized mechanisms of endocrine resistance suggesting the involvement of androgens as activators of the androgen receptor pathway and as stimulators of epidermal growth factor synthesis and function. Data from a series of prospective studies on operable breast cancer patients, showing high serum testosterone levels are associated to increased risk of recurrence, provide further support to a role for androgens in breast cancer progression. According to the above reported evidence, we proposed to counteract excessive androgen production in the adjuvant setting of estrogen receptor-positive patients and suggested selecting postmenopausal patients with elevated levels of serum testosterone, marker of ovarian hyperandrogenemia, for adjuvant treatment with a gonadotropins-releasing hormone analogue (medical oophorectomy) in addition to standard therapy with anti-estrogens. The proposed approach provides an attempt of personalized medicine that needs to be further investigated in clinical trials.

Sign in / Sign up

Export Citation Format

Share Document